<DOC>
	<DOCNO>NCT01832298</DOCNO>
	<brief_summary>RATIONAL : Simmitecan anticancer ester prodrug , involve activation chimmitecan . Chimmitecan，a novel CPT derivative , exhibit potent antitumor activity vitro vivo inhibit topoisomerase I . Also exert comparable effect topoisomerase I compare topotecan SN38 possess improved anticancer potency pharmacologic profile , compare clinically available CPT analogue . PURPOSE : determine maximum tolerate dose , safety profile pharmacokinetics Simmitecan .</brief_summary>
	<brief_title>Study Simmitecan Hydrochloride Treatment Advanced Solid Tumor</brief_title>
	<detailed_description />
	<criteria>Relapsed refractory standard therapy standard therapy available . At least one measurable lesion . Age = 18~65 year . ECOG=01 . Life expectancy ≥ 12 week . More 4 week operation , chemotherapy , radiotherapy , cytotoxic agent tyrosine kinase inhibitor . Adequate organ function : Haemoglobin ≥ 100 g/L , Absolute neutrophil count [ ANC ] ≥ 2×109/L , Platelets ≥ 100 × 109/L ) , Serum bilirubin ≤ 1.0×ULN , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 1.5×ULN ( If liver metastasis , serum transaminase ≤ 2.5×ULN ) , Creatinine clearance ≥ 50 mL/min , LVEF ≤ 50 % , QT interval ( correct Fridericia ) : male &lt; 450 m , female &lt; 470 ms Female : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Child bear potential , negative urine serum pregnancy test result initiate Famitinib . Male : All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Less 4 week last clinical trial . Known Spinal Cord compression disease brain pia mater CT /MRI screen . Patients ever severe diarrhea prior therapy camptothecin drug . Concurrent severe uncontrolled medical disease ( serious infection , serious diabetes ) Significant cardiovascular disease condition include ≥ class II cardiac function ( NYHA ) Acute chronic viral hepatitis . ( If HBsAg + , HBVDNA quantification ≤ LLN . ) Pregnant , lactation period men/women ready birth . Psychiatric disorder alter mental status . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>